Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J‐ROCKET AF Trials) in Asian Patients With Atrial Fibrillation

BACKGROUND: The ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) evaluated rivaroxaban (20/15 mg/d) versus warfarin in patients with atrial fibrillation. A separate trial, J‐ROCKE...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Yi‐Hsin, Lee, Hsin‐Fu, Wang, Chun‐Li, Chang, Shang‐Hung, Yeh, Chih‐Hsin, Chao, Tze‐Fan, Yeh, Yung‐Hsin, Chen, Shih‐Ann, Kuo, Chi‐Tai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6898830/
https://www.ncbi.nlm.nih.gov/pubmed/31623498
http://dx.doi.org/10.1161/JAHA.119.013053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6898830/
https://www.ncbi.nlm.nih.gov/pubmed/31623498
http://dx.doi.org/10.1161/JAHA.119.013053

Ejemplares similares